drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy
drug_description
Autologous gene-modified T cells engineered to express a bivalent CAR targeting CD79b and CD19, administered as a single IV infusion to mediate cytotoxic killing of malignant B cells and reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene-modified T cells expressing a bivalent CAR that binds CD19 and CD79b on malignant B cells; CAR engagement activates T-cell signaling, cytokine release, and cytotoxic killing, with dual targeting designed to limit antigen escape.
drug_name
CD79b-19 CAR T cells
nct_id_drug_ref
NCT06026319